US Stock MarketDetailed Quotes

XGN Exagen

Watchlist

3.060
-0.400-11.56%

Close Mar 3 16:00 ET

2.930
-0.130-4.25%

Pre 08:00 ET

53.97MMarket Cap-3.26P/E (TTM)

Exagen Stock Forum

Jaguar8

Jan 12 16:02

🟢 Watchlist JANUARY 13, 2025, Monday. NFA. Those with 🟢 are my top picks

NOTE!
1. NFA (Not Financial Advice!)
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, If you don’t a...

Jaguar8

Jan 12 12:01

NEWS

$Exagen (XGN.US)$
Exagen Inc. Secures Conditional NY State Approval for New Lupus and Rheumatoid Arthritis Biomarkers and Announces Select Preliminary 2024 Financial Results
Sunday, 12th January at 12:00 pm
New biomarkers on track for commercial launch in January 2025
Preliminary financial results indicate record full-year revenue and AVISE CTD trailing twelve-month ASP, with improvements to adjusted EBITDA and cash burn
CARLSBAD, Calif., Jan. 12, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:...

NEWS

$Exagen (XGN.US)$
Exagen Inc. Completes Validation and Regulatory Submission for New Lupus and Rheumatoid Arthritis Biomarkers on the AVISE® CTD Platform

Moomoo AI

Mar 22, 2024 14:11

Analysts predict Exagen's revenue growth to decelerate significantly, with an expected annual growth of 3.1% till 2024, compared to its past five-year growth rate of 7.5%. This is slower than the projected 18% annual growth of its industry peers.

The Exagen Inc. (NASDAQ:XGN) Annual Results Are Out And Analysts Have Published New Forecasts

Moomoo AI

Mar 20, 2024 05:41

The low P/S ratio and slower revenue growth have led to pessimism among shareholders about the company's future prospects. The company will need a significant change in fortune to justify a higher P/S ratio in the future.

Exagen Inc.'s (NASDAQ:XGN) 28% Dip In Price Shows Sentiment Is Matching Revenues

Dannymite

Mar 18, 2024 07:51

$Exagen (XGN.US)$ estimates beat!

Moomoo AI

Oct 24, 2023 05:47

Exagen's low P/S ratio indicates investor concerns over below-average expected revenue growth. For a higher P/S ratio or share price, conditions would need to improve. The recent drop in share price may be due to this potentially less favorable outlook.

Why Investors Shouldn't Be Surprised By Exagen Inc.'s (NASDAQ:XGN) 31% Share Price Plunge

No comment yet

XGN Exagen

Exagen Stock Forum

Trending Stocks